Alport Syndrome Indication Strategy Report 2026: COL4A5, Trials and Deal Signals uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.

ADPKD Indication Strategy Report 2026: AVPR2, PKD1, Trials and Market Outlook uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.

Diabetic Kidney Disease Indication Strategy Report 2026: SGLT2, MR, Trials and Whitespace uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.

Resistant Hypertension Indication Strategy Report 2026: Aldosterone, Trials and Whitespace uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.

Acute Coronary Syndrome Indication Strategy Report 2026: P2Y12, Trials and Market Outlook uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.

ASCVD Indication Strategy Report 2026: PCSK9, NLRP3, Trials and Deals uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.

ATTR-CM Indication Strategy Report 2026: TTR, Trials and $310M Deal Signal uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.

Hypertrophic Cardiomyopathy Indication Strategy Report 2026: Cardiac Myosin, Trials and Deals uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.

HFrEF Indication Strategy Report 2026: SGLT2, AT1R, Trials and Competitive Outlook uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.

HFpEF Indication Strategy Report 2026: SGLT2, MR, Trials and Deal Signals uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.

Pulmonary Arterial Hypertension Indication Strategy Report 2026: BMPR2, Trials and Deals uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.

Elevated Lipoprotein(a) Indication Strategy Report 2026: LPA, Trials and Market Opportunity uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.